Conducting clinical trials in "developing
nations" and other places that aren't part of the so-called First World has been great for some pharmas and biotechs in terms of cutting costs and
increasing recruitment, but the cost benefits won't last forever
Is it time for Health Canada to give up on regulation of drugs and medical devices, following the lead of the U.S. FDA on that front and focusing
on other public health duties for which it is better equipped?
At the crossroads of understanding cell physiology, disease pathology and etiology is cell metabolism, which is widely known
to be a common feature of these costly, debilitating and lethal diseases. In part because of this, The next decade will witness the release of a new class of
drugs, known as “metabolo-therapeutics,” which will target metabolic pathways and the individual metabolites that are required for the maintenance of normal